Cell transplantation for Huntington's disease. Should we continue?

Brain Research Bulletin

Volumn 72, Issue 2-3 SPEC. ISS., 2007, Pages 132-147

  Dunnett, Stephen B ^a   Rosser, Anne E ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Animal models; Brain repair; Clinical trials; Huntington's disease; Neurotransplantation

Indexed keywords

CELL TRANSPLANTATION; CLINICAL TRIAL; FEASIBILITY STUDY; HEALTH SURVEY; HEREDITY; HUMAN; HUNTINGTON CHOREA; METHODOLOGY; NEUROPATHOLOGY; NONHUMAN; PATIENT ASSESSMENT; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; SAFETY;

ANIMALS; BRAIN; CELL TRANSPLANTATION; CLINICAL TRIALS; HUMANS; HUNTINGTON DISEASE; NEURONS;

EID: 33847673272     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2006.10.019     Document Type: Review

References (122)

1. Albin R.L. Fetal striatal transplantation in Huntington's disease: time for a pause-the need to look at the rationale for fetal striatal transplantation. J. Neurol. Neurosurg. Psychiatr. 73 (2002) 612
2. Bach F.H., Fishman J.A., Daniels N., Proimos J., Anderson B., Carpenter C.B., Forrow L., Robson S.C., and Fineberg H.V. Uncertainty in xenotransplantation: individual benefit versus collective risk. Nat. Med. 4 (1998) 141-144
3. Bachoud-Lévi A.C., Bourdet C., Brugières P., Nguyen J.P., Grandmougin T., Haddad B., Jény R., Bartolomeo P., Boissé M.F., Dalla Barba G., Degos J.D., Ergis A.M., Lefaucheur J.P., Lisovoski F., Pailhous E., Rémy P., Palfi S., Defer G.L., Césaro P., Hantraye P., and Peschanski M. Safety and tolerability assessment of intrastriatal neural allografts in Huntington's disease patients. Exp. Neurol. 161 (2000) 194-202
4. Bachoud-Lévi A.C., Rémy P., Nguyen J.P., Brugières P., Lefaucheur J.P., Bourdet C., Baudic S., Gaura V., Maison P., Haddad B., Boissé M.F., Grandmougin T., Jény R., Bartolomeo P., Dalla Barba G., Degos J.D., Lisovski F., Ergis A.M., Pailhous E., Césaro P., Hantraye P., and Peschanski M. Motor and cognitive improvements in patients with Huntington's disease after neural transplantation. Lancet 356 (2000) 1975-1979
5. Bates G. Huntingtin aggregation and toxicity in Huntington's disease. Lancet 361 (2003) 1642-1644
6. Beal M.F., and Ferrante R.J. Experimental therapeutics in transgenic mouse models of Huntington's disease. Nat. Rev. Neurosci. 5 (2004) 373-384
7. Björklund A., Dunnett S.B., Brundin P., Stoessl A.J., Freed C.R., Breeze R.E., Levivier M., Peschanski M., Studer L., and Barker R. Neural transplantation for the treatment of Parkinson's disease. Lancet Neurol. 2 (2003) 437-445
8. Björklund A., and Lindvall O. Cell replacement therapies for central nervous system disorders. Nat. Neurosci. 3 (2000) 537-544
9. Boer G.J. Ethical guidelines for the use of human embryonic or fetal tissue for experimental and clinical neurotransplantation and research. J. Neurol. 242 (1994) 1-13
10. Boer G.J., and Widner H. Clinical neurotransplantation: core assessment protocol rather than sham surgery as control. Brain Res. Bull. 58 (2002) 547-553
11. Borlongan C.V., Cahill D.W., and Sanberg P.R. Asymmetrical behavior in rats following striatal lesions and fetal transplants: the elevated body swing test. Rest. Neurol. Neurosci. 9 (1995) 15-19
12. Broadwell R.D., Charlton H.M., Ebert P., Hickey W.F., Villegas J.C., and Wolf A.L. Angiogenesis and the blood-brain barrier in solid and dissociated cell grafts within the CNS. Prog. Brain Res. 82 (1990) 95-101
13. Brundin P., Dunnett S.B., Björklund A., and Nikkhah G. Transplanted dopaminergic neurons: more or less?. Nat. Med. 7 (2001) 512
14. Brundin P., Fricker R.A., and Nakao N. Paucity of P-zones in striatal grafts prohibit commencement of clinical trials in Huntington's disease. Neuroscience 71 (1996) 895-897
15. Ciechanover A., and Brundin P. The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg. Neuron 40 (2003) 427-446
16. Coyle J.T., and Schwarcz R. Lesions of striatal neurones with kainic acid provides a model for Huntington's chorea. Nature 263 (1976) 244-246
17. Deacon T., Schumacher J., Dinsmore J., Thomas C., Palmer P., Kott S., Edge A., Penney D., Kassissieh S., Dempsey P., and Isacson O. Histological evidence of fetal pig neural cell survival after transplantation into a patient with Parkinson's disease. Nat. Med. 3 (1997) 350-353
18. Deacon T.W., Pakzaban P., and Isacson O. The lateral ganglionic eminence is the origin of cells committed to striatal phenotypes: neural transplantation and developmental evidence. Brain Res. 668 (1994) 211-219
19. Defer G.L., Widner H., Marié R.M., Rémy P., and Levivier M. Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT-PD). Mov. Disord. 14 (1999) 572-584
20. Dunnett S.B. Functional repair of striatal systems by neural transplants: evidence for circuit reconstruction. Behav. Brain Res. 66 (1995) 133-142
21. Dunnett S.B., Björklund A., and Lindvall O. Cell therapy in Parkinson's disease-stop or go?. Nat. Rev. Neurosci. 2 (2001) 365-369
22. Dunnett S.B., Carter R.J., Watts C., Torres E.M., Mahal A., Mangiarini L., Bates G., and Morton A.J. Striatal transplantation in a transgenic mouse model of Huntington's disease. Exp. Neurol. 154 (1998) 31-40
23. Dunnett S.B., Meldrum A., and Muir J.L. Frontal-striatal disconnection disrupts cognitive performance of the frontal-type in the rat. Neuroscience 155 (2005) 1055-1065
24. Dunnett S.B., Nathwani F., and Björklund A. The integration and function of striatal grafts. Prog. Brain Res. 127 (2000) 345-380
25. Dunnett S.B., and Rosser A.E. Cell therapy in Huntington's disease. NeuroRx 1 (2004) 394-405
26. Dunnett S.B., White A., Heath J., Torres E.M., and Gates R.A. Striatal grafts alleviate bilateral striatal lesion deficits in operant delayed alternation in the rat. Exp. Neurol. 199 (2006) 478-489
27. European Parliament and Council, Directive 2004/23/EC of 31 March 2004, on setting standards of quality and safety for the donation, procurement, testing, processing, preservation, storage and distribution of human tissues and cells. Off. J. Eur. Union L102 (2004) 48-58.
28. Farrington M., Wreghitt T.G., Lever A.M., Dunnett S.B., Rosser A.E., and Barker R.A. Neural transplantation in Huntington's disease: NEST-UK donor tissue microbiological screening programme and review of the literature. Cell Transplant. 15 (2006) 279-289
29. Fawcett J.W., Rosser A.E., and Dunnett S.B. Brain Damage Brain Repair (2001), Oxford University Press, Oxford
30. Fink J.S., Schumacher J.M., Ellias S.A., Palmer E.P., Saint-Hilaire M., Shannon K., Penn R., Starr P., Van Horne C., Kott H.S., Dempsey P.K., Fischman A.J., Raineri R., Manhart C., Dinsmore J., and Isacson O. Porcine xenografts in Parkinson's disease and Huntington's disease patients: preliminary results. Cell Transplant. 9 (2000) 273-278
31. Folkerth R.D., and Durso R. Survival and proliferation of non-neural tissues, with obstruction of cerebral ventricles, in a Parkinsonian patient treated with fetal allografts. Neurology 46 (1996) 1219-1225
32. Freeman T.B., Cicchetti F., Hauser R.A., Deacon T.W., Li X.J., Hersch S.M., Nauert G.M., Sanberg P.R., Kordower J.H., Saporta S., and Isacson O. Transplanted fetal striatum in Huntington's disease: phenotypic development and lack of pathology. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 13877-13882
33. Freeman T.B., Vawter D.E., Leaverton P.E., Godbold J.H., Hauser R.A., Goetz C.G., and Olanow C.W. Use of placebo surgery in controlled trials of a cellular-based therapy for Parkinson's disease. N. Engl. J. Med. 341 (1999) 988-992
34. Fricker R.A., Torres E.M., Hume S.P., Myers R., Opacka-Juffry J., Ashworth S., and Dunnett S.B. The effects of donor stage on the survival and function of embryonic striatal grafts. II: Correlation between positron emission tomography and reaching behaviour. Neuroscience 79 (1997) 711-722
35. Furtado S., Sossi V., Hauser R.A., Samii A., Schulzer M., Murphy C.B., Freeman T.B., and Stoessl A.J. Positron emission tomography after fetal transplantation in Huntington's disease. Ann. Neurol. 58 (2005) 331-337
36. Gaura V., Bachoud-Lévi A.C., Ribeiro M.J., Nguyen J.P., Frouin V., Baudic S., Brugières P., Mangin J.F., Boissé M.F., Palfi S., Césaro P., Samson Y., Hantraye P., Peschanski M., and Rémy P. Striatal neural grafting improves cortical metabolism in Huntington's disease patients. Brain 127 (2004) 65-72
37. Gerhard A., Banati R.B., Goerres G.B., Cagnin A., Myers R., Gunn R.N., Turkheimer F., Good C.D., Mathias C.J., Quinn N., Schwarz J., and Brooks D.J. [11C](R)-PK11195 PET imaging of microglial activation in multiple system atrophy. Neurology 61 (2003) 686-689
38. Grasbon-Frodl E.M., Nakao N., Lindvall O., and Brundin P. Phenotypic development of the human embryonic striatal primordium: a study of cultured and grafted neurons from the lateral and medial ganglionic eminence. Neuroscience 73 (1996) 171-183
39. Grasbon-Frodl E.M., Nakao N., Lindvall O., and Brundin P. Developmental features of human striatal tissue transplanted in a rat model of Huntington's disease. Neurobiol. Dis. 3 (1997) 299-311
40. Graybiel A.M., Liu F.C., and Dunnett S.B. Intrastriatal grafts derived from fetal striatal primordia. 1: Phenotypy and modular organization. J. Neurosci. 9 (1989) 3250-3271
41. Greenamyre J.T., and Shoulson I. We need something better and we need it now-fetal striatal transplantation in Huntington's disease?. Neurology 58 (2002) 675-676
42. Hagell P., Schrag A., Piccini P., Jahanshahi M., Brown R., Rehncrona S., Widner H., Brundin P., Rothwell J.C., Odin P., Wenning G.K., Morrish P., Gustavii B., Björklund A., Brooks D.J., Marsden C.D., Quinn N.P., and Lindvall O. Sequential bilateral transplantation in Parkinson's disease-effects of the second graft. Brain 122 (1999) 1121-1132
43. Hauser R.A., Freeman T.B., Snow B.J., Nauert M., Gauger L., Kordower J.H., and Olanow C.W. Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease. Arch. Neurol. 56 (1999) 179-187
44. Hauser R.A., Furtado S., Cimino C.R., Delgado H., Eichler S., Schwartz S., Scott D., Nauert G.M., Soety E., Sossi V., Holt D.A., Sanberg P.R., Stoessl A.J., and Freeman T.B. Bilateral human fetal striatal transplantation in Huntington's disease. Neurology 58 (2002) 687-695
45. Hauser R.A., Sandberg P.R., Freeman T.B., and Stoessl A.J. Bilateral human fetal striatal transplantation in Huntington's disease. Neurology 58 (2002) 1704
46. Hickey M.A., and Chesselet M.F. Apoptosis in Huntington's disease. Prog. Neurol. 27 (2003) 255-265
47. Hoang T.Q., Bluml S., Dubowitz D.J., Moats R., Kopyov O., Jacques D., and Ross B.D. Quantitative proton-decoupled 31P MRS and 1H MRS in the evaluation of Huntington's and Parkinson's diseases. Neurology 50 (1998) 1033-1040
48. Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72 (1993) 971-983
49. Hurelbrink C.B., Tyers P., Armstrong R.J.E., Dunnett S.B., Barker R.A., and Rosser A.E. Long-term hibernation of human fetal striatal tissue does not adversely affect its differentiation in vitro or graft survival: implications for clinical trials in Huntington's disease. Cell Transplant. 12 (2003) 687-695
50. Isacson O., Brundin P., Kelly P.A.T., Gage F.H., and Björklund A. Functional neuronal replacement by grafted striatal neurons in the ibotenic acid lesioned rat striatum. Nature 311 (1984) 458-460
51. Kelly C.M., Rosser A.E., and Dunnett S.B. Neuronal cells for transplantation in Huntington's disease. In: Davis-Sanberg C., and Sanberg P.R. (Eds). Cell Therapy for Brain Repair (2006), Humana Press, Totowa 83-115
52. Kendall A.L., Rayment D., Aigbirhio F., Baker H.F., Chandler R., Clark J., Dettman C., Dunnett S.B., Jeavons A., Page K., Ridley R.M., Torres E.M., Turkheimer F., and Visvikis D. In vivo PET analysis of the status of striatal allografts in the common marmoset. Eur. J. Neurosci. 10 Suppl. (1999) 370
53. Kendall A.L., Rayment F.D., Torres E.M., Baker H.F., Ridley R.M., and Dunnett S.B. Functional integration of striatal allografts in a primate model of Huntington's disease. Nat. Med. 4 (1998) 727-729
54. Kirik D., and Björklund A. Histological analysis of fetal dopamine cell suspension grafts in two patients with Parkinson's disease gives promising results. Brain 128 (2005) 1478-1479
55. Kopyov O.V., Jacques S., Kurth M., Philpott L.M., Lee A., Patterson M., Duma C., Lieberman A., and Eagle K.S. Fetal transplantation for Huntington's disease: clinical studies. In: Freeman T.B., and Kordower J.H. (Eds). Cell Transplantation for Neurological Disorders (1998), Humana Press, Totowa, NJ 95-134
56. Kopyov O.V., Jacques S., Lieberman A., Duma C.M., and Eagle K.S. Safety of intrastriatal neurotransplantation for Huntington's disease patients. Exp. Neurol. 119 (1998) 97-108
57. Kordower J.H., Goetz C.G., Freeman T.B., and Olanow C.W. Dopaminergic transplants in patients with Parkinson's disease: neuroanatomical correlates of clinical recovery. Exp. Neurol. 144 (1997) 41-46
58. Kurth M.C., Kopyov O., and Jacques D.B. Improvement in motor function after fetal transplantation in a patient with Huntington's disease. Neurology 46 (1996) 22006
59. Langston J.W., Widner H., and Goetz C.G. Core assessment program for intracerebral transplantation (CAPIT). Mov. Disord. 7 (1992) 2-13
60. Leigh K., Elisevich K., and Rogers K.A. Vascularization and microvascular permeability in solid versus cell-suspension embryonic neural grafts. J. Neurosurg. 81 (1994) 272-283
61. Lindvall O., and Hagell P. Clinical observations after neural transplantation in Parkinson's disease. Prog. Brain Res. 127 (2000) 299-320
62. Madrazo I., Franco-Bourland R.E., Castrejon H., Cuevas C., and Ostrosky-Solis F. Fetal striatal homotransplantation for Huntington's disease: first two case reports. Neurol. Res. 17 (1995) 312-315
63. Mamelak A.N., Eggerding F.A., Oh D.S., Wilson E., Davis R.L., Spitzer R., Hay J.A., and Caton III W.L. Fatal cyst formation after fetal mesencephalic allograft transplant for Parkinson's disease. J. Neurosurg. 89 (1998) 592-598
64. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., Lawton M., Trottier Y., Lehrach H., Davies S.W., and Bates G.P. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87 (1996) 493-506
65. Mazzocchi-Jones D., Döbrössy M.D., and Dunnett S.B. Synaptic plasticity in striatal grafts. In: Bolam J.P., Ingham C.A., and Magill P.J. (Eds). The Basal Ganglia VIII (2005), Springer, New York 313-320
66. Medical Research Council, Guidelines for Good Clinical Practice, Medical Research Council, London, 1998.
67. Menalled L.B., and Chesselet M.F. Mouse models of Huntington's disease. Trends Pharmacol. Sci. 23 (2002) 32-39
68. Murphy F.A. The public health risk of animal organ and tissue transplantation into humans. Science 273 (1996) 746-747
69. Naimi S., Jény R., Hantraye P., Peschanski M., and Riche D. Ontogeny of human striatal DARPP-32 neurons in fetuses and following xenografting to the adult rat brain. Exp. Neurol. 137 (1996) 15-25
70. Nakao N., Ogura M., Nakai K., and Itakura T. Embryonic striatal grafts restore neuronal activity of the globus pallidus in a rodent model of Huntington's disease. Neuroscience 88 (1999) 469-477
71. Nikkhah G., Cunningham M.G., Jödicke A., Knappe U., and Björklund A. Improved graft survival and striatal reinnervation by microtransplantation of fetal nigral cell suspensions in the rat Parkinson model. Brain Res. 633 (1994) 133-143
72. Nishino H., Koide K., Aihara N., Kumazaki M., Sakurai T., and Nagai H. Striatal grafts in the ischemic striatum improve pallidal GABA release and passive avoidance. Brain Res. Bull. 32 (1993) 517-520
73. Olsson M., Björklund A., and Campbell K. Early specification of striatal projection neurons and interneuronal subtypes in the lateral and medial ganglionic eminence. Neuroscience 84 (1998) 867-876
74. Olsson M., Campbell K., Wictorin K., and Björklund A. Projection neurons in fetal striatal transplants are predominantly derived from the lateral ganglionic eminence. Neuroscience 69 (1995) 1169-1182
75. Onions D., Hart D., Mahoney C., Galbraith D., and Smith K. Endogenous retroviruses and the safety of porcine xenotransplantation. Trends Microbiol. 6 (1998) 430-431
76. Pakzaban P., Deacon T.W., Burns L.H., Dinsmore J., and Isacson O. A novel mode of immunoprotection of neural xenotransplants: masking of donor major histocompatibility complex class I enhances transplant survival in the central nervous system. Neuroscience 65 (1995) 983-996
77. Pakzaban P., Deacon T.W., Burns L.H., and Isacson O. Increased proportion of acetylcholinesterase-rich zones and improved morphological integration in host striatum of fetal grafts derived from the lateral but not the medial ganglionic eminence. Exp. Brain Res. 97 (1993) 13-22
78. Palfi S., Condé F., Riche D., Brouillet E., Dautry C., Mittoux V., Hantraye P., and Peschanski M. Fetal striatal allografts reverse cognitive deficits in a primate model of Huntington's disease. Nat. Med. 4 (1998) 963-966
79. Palfi S., Nguyen J.P., Brugières P., LeGuerinel C., Hantraye P., Rémy P., Rostaing S., Defer G.L., Césaro P., Keravel Y., and Peschanski M. MRI-stereotactical approach for neural grafting in basal ganglia disorders. Exp. Neurol. 150 (1998) 272-281
80. Pavese N., Andrews T.C., Brooks D.J., Ho A.K., Rosser A.E., Barker R.A., Robbins T.W., Sahakian B.J., Dunnett S.B., and Piccini P. Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study. Brain 126 (2003) 1127-1135
81. Pavese N., Andrews T.C., Brooks D.J., Rosser A.E., Barker R.A., Dunnett S.B., Sahakian B.J., and Piccini P. Huntington's disease progression measured with serial [11C]-raclopride PET and the UHDRS. Neurology 56 (2001) A385
82. Peschanski M., Césaro P., and Hantraye P. Rationale for intrastriatal grafting of striatal neuroblasts in patients with Huntington's disease. Neuroscience 68 (1995) 273-285
83. Peschanski M., Césaro P., and Hantraye P. What is needed versus what would be interesting to know before undertaking neural transplantation in patients with Huntington's disease. Neuroscience 71 (1996) 899-900
84. Peschanski M., and Dunnett S.B. Cell therapy for Huntington's disease, the next step forward. Lancet Neurol. 1 2 (2002) 81
85. Philpott L.M., Kopyov O.V., Lee A.J., Jacques S., Duma C.M., Caine S., Yang M., and Eagle K.S. Neuropsychological functioning following fetal striatal transplantation in Huntington's chorea: three case presentations. Cell Transplant. 6 (1997) 203-212
86. Piccini P., Brooks D.J., Björklund A., Gunn R.N., Grasby P.M., Rimoldi O., Brundin P., Hagell P., Rehncrona S., Widner H., and Lindvall O. Dopamine release from nigral transplants visualised in vivo in a Parkinson's patient. Nat. Neurosci. 2 (1999) 1137-1140
87. Piccini P., Lindvall O., Björklund A., Brundin P., Hagell P., Ceravolo R., Oertel W., Quinn N., Samuel M., Rehncrona S., Widner H., and Brooks D.J. Delayed recovery of movement-related cortical function in Parkinson's disease after striatal dopaminergic grafts. Ann. Neurol. 48 (2000) 689-695
88. Piccini P., Pavese N., Hagell P., Reimer J., Björklund A., Oertel W.H., Quinn N.P., Brooks D.J., and Lindvall O. Factors affecting the clinical outcome after neural transplantation in Parkinson's disease. Brain (2005)
89. Platt J.L. Xenotransplantation-new risks, new gains. Nature 407 (2000) 27-30
90. S. Polgar, J. Ng, Ethics, methodology and the use of placebo controls in surgical trials. Am. J. Bioethics, submitted for publication.
91. Polkinghorne J., Hoffenberg R., Kennedy I., and Macintyre S. Review of the Guidance on the Research Use of Fetuses and Fetal Material (1989), HMSO, London
92. Pritzel M., Isacson O., Brundin P., Wiklund L., and Björklund A. Afferent and efferent connections of striatal grafts implanted into the ibotenic acid lesioned neostriatum in adult rats. Exp. Brain Res. 65 (1986) 112-126
93. Pundt L.L., Kondoh T., Conrad J.A., and Low W.C. Transplantation of human striatal tissue into a rodent model of Huntington's disease: phenotypic expression of transplanted neurons and host-to-graft innervation. Brain Res. Bull. 39 (1996) 23-32
94. Quinn N.P. The clinical application of cell grafting techniques in patients with Parkinson's disease. Prog. Brain Res. 82 (1990) 619-625
95. Quinn N.P., Brown R., Craufurd D., Goldman S., Hodges J.R., Kieburtz K., Lindvall O., MacMillan J.C., and Roos R.A.C. Core assessment programme for intracerebral transplantation in Huntington's disease (CAPIT-HD). Mov. Disord. 11 (1996) 143-150
96. 18F]fluorodopa uptake in five grafted Parkinsonian patients. Ann. Neurol. 38 (1995) 580-588
97. Ross B.D., Hoang T.Q., Blüml S., Dubowitz D.J., Kopyov O.V., Jacques D.B., Lin A., Seymour K., and Tan J. In vivo magnetic resonance spectroscopy of human fetal neural transplants. NMR Biomed. 12 (1999) 221-236
98. Ross C.A. Huntington's disease: new paths to pathogenesis. Cell 118 (2004) 4-7
99. Rosser A.E., Barker R.A., Armstrong R.A., Elneil S., Jain M., Hurelbrink C.B., Prentice A., Carne C., Thornton S.R., Hutchinson H., and Dunnett S.B. Staging and preparation of human fetal striatal tissue for UK study of neural transplantation in Huntington's disease. Cell Transplant. 12 (2003) 679-686
100. Rosser A.E., Barker R.A., Guillard J., Harrower T., Watts C., Pickard J., Dunnett S.B., and the NEST-UK consortium. Unilateral transplantation of human primary fetal tissue in four patients with Huntington's disease: NEST-UK safety report (ISRCTN no. 36485475). J. Neurol. Neurosurg. Psychiatr. 73 (2002) 678-685
101. Sathasivam K., Hobbs C., Mangiarini L., Mahal A., Turmaine M., Doherty P., Davies S.W., and Bates G.P. Transgenic models of Huntington's disease. Philos. Trans. R. Soc. Lond. B 354 (1999) 963-969
102. Sauer H., and Brundin P. Effects of cool storage on survival and function of intrastriatal ventral mesencephalic grafts. Rest. Neurol. Neurosci. 2 (1991) 123-135
103. 18F]-6-l-fluorodopa PET studies of graft and host dopaminergic function following fetal mesencephalic transplantation. Adv. Neurol. 60 (1993) 715-720
104. Sawle G.V., and Myers R. The role of positron emission tomography in the assessment of human neurotransplantation. Trends Neurosci. 16 (1993) 172-176
105. Schilling G., Savonenko A.V., Coonfield M.L., Morton J.L., Vorovich E., Gale A., Neslon C., Chan N., Eaton M., Fromholt D., Ross C.A., and Borchelt D.R. Environmental, pharmacological, and genetic modulation of the HD phenotype in transgenic mice. Exp. Neurol. 187 (2004) 137-149
106. Schmidt R.H., Björklund A., and Stenevi U. Intracerebral grafting of dissociated CNS tissue suspensions: a new approach for neuronal transplantation to deep brain sites. Brain Res. 218 (1981) 347-356
107. Schwarcz R., Hökfelt T., Fuxe K., Jonsson G., Goldstein M., and Terenius L. Ibotenic acid-induced neuronal degeneration: a morphological and neurochemical study. Exp. Brain Res. 37 (1979) 199-216
108. Schwarcz R., Whetsell W.O., and Mangano R.M. Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. Science 219 (1983) 316-318
109. Shannon K.M., and Kordower J.H. Neural transplantation for Huntington's disease: experimental rationale and recommendations for clinical trials. Cell Transplant. 5 (1996) 339-352
110. Smart I.H.M., and Sturrock R.R. Ontogeny of the neostriatum. In: Divac I., and Öberg R.G.E. (Eds). The Neostriatum (1979), Pergamon Press, New York 127-146
111. Sofroniew M.V., Dunnett S.B., and Isacson O. Remodeling of intrinsic and afferent systems in neocortex with cortical transplants. Prog. Brain Res. 82 (1990) 313-320
112. Sramka M., Rattaj M., Molina H., Vojtassak J., Belan V., and Ruzicky E. Stereotactic technique and pathophysiological mechanisms of neurotransplantation in Huntington's chorea. Stereotact. Funct. Neurosurg. 58 (1992) 79-83
113. Stenevi U., Björklund A., and Svendgaard N.-A. Transplantation of central and peripheral monoamine neurons to the adult rat brain: techniques and conditions for survival. Brain Res. 114 (1976) 1-20
114. Stoye J.P., Le Tissier P., Takeuchi Y., Patience C., and Weiss R.A. Endogenous retroviruses: a potential problem for xenotransplantation?. Ann. N.Y. Acad. Sci. 862 (1998) 67-74
115. Torres E.M., Fricker R.A., Hume S., Myers R., Opacka-Juffry J., Ashworth S., Brooks D.J., and Dunnett S.B. Assessment of striatal graft viability in the rat in vivo using a small diameter PET scanner. NeuroReport 6 (1995) 2017-2021
116. Watts C., Brasted P.J., and Dunnett S.B. The morphology, integration and functional efficacy of striatal grafts differs between cell suspensions and tissue pieces. Cell Transplant. 9 (2000) 395-407
117. Watts C., Brasted P.J., Eagle D.M., and Dunnett S.B. Embryonic donor age and dissection influence striatal graft development and functional integration in a rodent model of Huntington's disease. Exp. Neurol. 163 (2000) 85-97
118. Watts C., Donovan T., Gillard H., Antoun N.M., Burnstein R., Menon D.K., Carpenter T.A., Fryer T., Thomas D.G.T., and Pickard J.D. Evaluation of an MRI-based protocol for cell implantation in four patients with Huntington's disease. Cell Transplant. 12 (2003) 697-704
119. Wictorin K. Anatomy and connectivity of intrastriatal striatal transplants. Prog. Neurobiol. 38 (1992) 611-639
120. Wictorin K., and Björklund A. Connectivity of striatal grafts implanted into the ibotenic acid-lesioned striatum. 2: Cortical afferents. Neuroscience 30 (1989) 297-311
121. Wictorin K., Isacson O., Fischer W., Nothias F., Peschanski M., and Björklund A. Connectivity of striatal grafts implanted into the ibotenic acid-lesioned striatum. 1: Subcortical afferents. Neuroscience 27 (1988) 547-562
122. Wictorin K., Simerly R.B., Isacson O., Swanson L.W., and Björklund A. Connectivity of striatal grafts implanted into the ibotenic acid-lesioned striatum. 3: Efferent projecting graft neurons and their relation to host afferents within the grafts. Neuroscience 30 (1989) 313-330